8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates

Intravenous general anaesthetic induction agents produce rapid transition from consciousness to unconsciousness, typically within one arm-brain circulation time (30 to 40 seconds). Selecting the appropriate agent demands detailed mastery of their distinct receptor targets, formulation chemistry, pharmacokinetic modeling, hemodynamic profiles, and clinical toxicity syndromes.

---

1. Comparative Molecular Targets and Pharmacokinetic Modeling

General anaesthetics modulate central nervous system transmission by either enhancing inhibitory signaling or attenuating excitatory pathways.

                                [ RECEPTOR PROFILES ]
                                          |
        +---------------------------------+---------------------------------+
        |                                                                   |
   [ INHIBITORY ]                                                      [ EXCITATORY ]
   GABA_A Receptor Potentiation                                        NMDA Receptor Antagonism
   - Propofol ($\beta$-subunit interfaces)                             - Ketamine (Non-competitive
   - Etomidate ($\beta_2, \beta_3$ subunits)                             pore blockade at PCP site)
   - Thiopental (Prolongs channel opening duration)                    - Prevents glutamate & glycine
   - Influx of $Cl^-$ $\rightarrow$ Hyperpolarization                    activation of cation channels

The Multicompartment Pharmacokinetic Model

Following an intravenous bolus, induction agents distribute according to a three-compartment mammillary model:

1. Central Compartment ($V_1$): Intravascular blood volume and vessel-rich group (VRG: brain, heart, lungs, liver, kidneys), receiving 75% of cardiac output.
2. Intermediate Compartment ($V_2$): Muscle and skin.
3. Peripheral Compartment ($V_3$): Adipose tissue and poorly perfused tissues.

Awakening following a solitary induction bolus is governed by the distribution half-life ($t_{1/2\alpha}$)—the rapid physical redistribution of drug molecules from the vessel-rich brain ($V_1$) into the larger vessel-intermediate muscle reservoir ($V_2$). The terminal elimination half-life ($t_{1/2\beta}$) reflects hepatic/extrahepatic clearance and has virtually no role in terminating a single bolus dose.

Context-Sensitive Half-Time (CSHT)

The context-sensitive half-time is the time required for the central compartment drug concentration to decrease by 50% following termination of a steady-state continuous infusion of a given duration ("context").

• Propofol: Exhibits a remarkably flat CSHT curve (<40 minutes even after continuous 8-hour infusions) due to rapid total body clearance exceeding hepatic blood flow.
• Thiopental: Exhibits an exponential, steep CSHT curve; continuous infusion saturates peripheral adipose stores, converting distribution into zero-order elimination kinetics with context-sensitive half-times extending across days.
• Ketamine and Etomidate: Display intermediate CSHT profiles.

---

2. Propofol (2,6-diisopropylphenol)

Propofol is an alkylphenol derivative that remains the worldwide gold standard for intravenous induction and Total Intravenous Anaesthesia (TIVA).

                           OH
                         /    \
               (H_3C)_2HC      CH(CH_3)_2
                         \    /
                           ---
                 2,6-diisopropylphenol

Mechanism of Action

Propofol acts as a positive allosteric modulator at the pentameric $GABA_A$ receptor complex, binding to cavities formed by the transmembrane segments at the $\beta$-subunit interfaces (point mutation of $\beta_3$ N265 abolishes much of its effect in animal models). Binding increases the affinity of the receptor for endogenous $\gamma$-aminobutyric acid ($GABA$), prolonging inhibitory postsynaptic currents by maintaining the $Cl^-$ channel in an open configuration. At supratherapeutic concentrations, propofol directly gates and opens the chloride ionophore independent of GABA.

Formulation and Additives

Propofol is highly lipophilic and virtually insoluble in aqueous solutions. It is formulated as a 1% (10 mg/mL) or 2% (20 mg/mL) oil-in-water macroemulsion:

• 10% Soybean Oil: Solvent providing the lipid core.
• 2.25% Glycerol: Osmotic agent to establish isotonicity.
• 1.2% Purified Egg Phosphatide (Egg Lecithin): Surfactant emulsifier derived exclusively from egg yolk.

Allergy Considerations: Egg allergy is predominantly triggered by proteins located in egg white (ovalbumin, ovomucoid). True anaphylaxis to purified egg yolk phosphatide is extraordinarily rare. Cross-reactivity in patients with isolated peanut or soy allergies is clinically negligible in modern practice, though caution is warranted in patients with documented severe anaphylaxis to refined soybean oil.

Antimicrobial Retardants:

• Disodium Edetate (EDTA, 0.005%): Present in Diprivan; chelates divalent metal ions to inhibit bacterial and fungal proliferation.
• Sodium Metabisulfite (0.025%): Present in generic formulations; carries a risk of precipitating acute bronchospasm in sulfite-sensitive asthmatic patients.

Pharmacokinetics and Metabolism

• Distribution: Rapid $t_{1/2\alpha}$ of 2 to 4 minutes accounts for prompt recovery 8 to 10 minutes after a single bolus of 1.5 to 2.5 mg/kg.
• Clearance: Total body clearance is exceptionally high ($1.5-2.2\text{ L/min}$), significantly exceeding normal hepatic blood flow (~$1.2-1.5\text{ L/min}$). This disparity confirms substantial extrahepatic clearance, predominantly via uptake and first-pass metabolism in the pulmonary vascular bed and renal glucuronide conjugation.
• Metabolites: Glucuronide and sulfate conjugates excreted in urine; non-toxic and inactive.

Organ System Effects

• Cardiovascular: Produces the most pronounced hypotension among induction agents. Arterial blood pressure drops by 20% to 30% due to potent arterial vasodilation (decreased systemic vascular resistance, SVR) and direct venodilation (decreased cardiac preload). Propofol exerts direct negative inotropic effects and uniquely blunts the baroreceptor reflex, preventing the compensatory tachycardia typically provoked by arterial hypotension.
• Respiratory: Causes profound dose-dependent respiratory depression and apnea. Blunts the ventilatory drive response to arterial hypercapnia and hypoxemia. Strongly inhibits pharyngeal and laryngeal protective airway reflexes, permitting placement of a supraglottic airway (LMA) without neuromuscular blockade.
• Central Nervous System: Decreases cerebral metabolic rate of oxygen ($CMRO_2$) by ~35%, reducing cerebral blood flow ($CBF$) and intracranial pressure ($ICP$). Cerebrovascular autoregulation and carbon dioxide reactivity are preserved. Possesses potent anticonvulsant properties at anaesthetic doses.
• Ancillary Benefits: Exerts antiemetic effects at subhypnotic doses (10 to 20 mg IV bolus or low-dose infusion); the mechanism is uncertain but may involve reduced serotonin concentrations in the area postrema. Possesses antipruritic activity against neuraxial opioid-induced pruritus.
• Pain on Injection: Occurs in up to 70% of unmedicated patients due to activation of the endothelial kallikrein-kinin cascade. Prevented by using large antecubital veins, co-administering intravenous lidocaine (0.5 mg/kg), or pretreating with short-acting opioids.

Propofol Infusion Syndrome (PRIS)

PRIS is a catastrophic, high-mortality metabolic derangement triggered by prolonged, high-dose infusions:

   High-Dose Propofol (>4-5 mg/kg/h for >48 h) + Stress / Sepsis / Catecholamines
                                      |
        +-----------------------------+-----------------------------+
        |                                                           |
[ CPT-1 Inhibition ]                                    [ Complex I & IV Blockade ]
Fatty acids cannot enter mitochondria                   Electron transport chain uncoupled
        |                                                           |
        v                                                           v
  Free Fatty Acids Accumulate in Blood                      Severe ATP Depletion
  (Hepatomegaly, Steatosis, Hypertriglyceridemia)           (Cellular Starvation & Lysis)
        |                                                           |
        +-----------------------------+-----------------------------+
                                      |
                                      v
  [ Massive Rhabdomyolysis -> Myoglobinuria -> Acute Renal Failure ]
  [ Severe Lactic Acidosis + Refractory Hyperkalemia ]
  [ Brugada-like ECG Pattern (Coved ST elevation, RBBB) -> Asystolic Arrest ]

• Pathophysiology: Propofol impairs mitochondrial entry of long-chain free fatty acids by inhibiting carnitine palmitoyltransferase-1 (CPT-1) and disrupts the mitochondrial electron transport chain (inhibition at several respiratory-chain sites has been described). When intracellular carbohydrate stores become depleted, cells starve of ATP, inducing widespread cytolysis.
• Risk Factors: Propofol infusion rate $>4-5\text{ mg/kg/h}$ ($>67-83\text{ }\mu\text{g/kg/min}$) for $>48\text{ hours}$, critical illness, severe head trauma, concurrent exogenous catecholamine infusions, high-dose corticosteroids, and low carbohydrate intake.
• Diagnostic Criteria: Unexplained, refractory high anion gap metabolic acidosis with hyperlactatemia, severe rhabdomyolysis (peaking creatine kinase >10,000 U/L, myoglobinuria), hyperkalemia, acute tubular necrosis, hepatomegaly with fatty microvesicular infiltration, hypertriglyceridemia, and progressive cardiovascular failure.
• ECG Sign: Development of a right bundle branch block (RBBB) pattern with coved ST-segment elevation in the right precordial leads ($V_1-V_3$) mimicking Brugada syndrome, rapidly progressing to refractory ventricular fibrillation or electromechanical dissociation.
• Management: Immediate cessation of propofol; aggressive hemodynamic support with vasopressors and inotropes; continuous renal replacement therapy (hemodiafiltration) for potassium, lactate, and myoglobin clearance; and emergency venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO).

---

3. Etomidate

Etomidate is a carboxylated imidazole derivative synthesized as a pure $R(+)$-enantiomer, possessing 10-fold greater hypnotic potency than its $S(-)$-isomer.

Formulation and Receptor Mechanism

• Formulation: Poorly water-soluble; dissolved in 35% propylene glycol (osmolality ~4,600 mOsm/L). This hypertonic vehicle produces severe pain on injection (up to 40%) and a high rate of sterile superficial thrombophlebitis. Liposomal lipid formulations mitigate these local vascular complications.
• Mechanism: Selectively enhances $GABA_A$ receptor activity by binding to transmembrane sites on the $\beta_2$ and $\beta_3$ subunits.

Hemodynamic Stability: The Clinical Niche

Etomidate is the induction agent of choice in patients with severe cardiovascular compromise (e.g., critical aortic stenosis, severe congestive heart failure, acute hypovolemic shock, cardiac tamponade). It causes virtually no myocardial depression, no peripheral vasodilation, and no blunting of sympathetic baroreceptor reflexes. Cardiac output, stroke volume, myocardial contractility, and systemic vascular resistance remain completely stable, maintaining critical coronary perfusion pressure.

Central Nervous System and Adverse Effects

• Neurodynamics: Decreases $CMRO_2$ (by 35-45%), $CBF$, and $ICP$. Cerebral perfusion pressure ($CPP = MAP - ICP$) is preserved or augmented due to constant arterial pressure.
• Myoclonus: Involuntary, uncoordinated skeletal muscle contractions occur in 30% to 60% of patients following induction. This myoclonus does not reflect cortical epileptic discharge; rather, it arises from transient subcortical disinhibition of inhibitory motor circuits. It is attenuated by prior administration of midazolam or low-dose opioids.
• Postoperative Nausea and Vomiting (PONV): Etomidate produces the highest incidence of PONV among all intravenous induction agents (exceeding 30-40%).

Adrenocortical Suppression

Etomidate causes profound, dose-dependent, reversible inhibition of mitochondrial $11\beta$-hydroxylase (CYP11B1) within the adrenal cortex.

                        Cholesterol
                            |
                   11-Deoxycortisol
                            |
               [ 11-beta-hydroxylase (CYP11B1) ] <--- INHIBITED BY ETOMIDATE
                            |                          (Imidazole ring binds
                            x                           cytochrome heme iron)
                         Cortisol
                            |
              [ Adrenocortical Failure ]

• Enzymatic Defect: The free imidazole nitrogen of etomidate binds with exceptionally high affinity to the catalytic heme iron of $11\beta$-hydroxylase, blocking the hydroxylation of 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone/aldosterone.
• Clinical Impact: A single induction bolus of $0.3\text{ mg/kg}$ produces primary adrenocortical insufficiency, abolishing the plasma cortisol response to adrenocorticotropic hormone (ACTH / synacthen stimulation) for 24 to 48 hours.
• Continuous Infusion Prohibition: In the 1980s, continuous etomidate sedation in intensive care trauma units increased mortality threefold due to fulminant adrenocortical failure. Continuous infusions of etomidate are absolutely contraindicated.

---

4. Ketamine

Ketamine is a synthetic arylcyclohexylamine derivative structurally related to phencyclidine (PCP). It is commercially prepared as a racemic mixture of $R(-)$ and $S(+)$ enantiomers or as pure $S(+)$-ketamine (esketamine).

$S(+)$-Ketamine vs Racemic Ketamine

The $S(+)$-isomer exhibits 2 to 4 times higher binding affinity for the NMDA receptor than $R(-)$-ketamine. It provides equivalent hypnotic depth and profound analgesia at half the clinical dose, exhibits a 20% higher systemic clearance rate, produces less psychotomimetic emergence agitation, and enables faster cognitive recovery.

Molecular Mechanism of Dissociative Anaesthesia

Ketamine produces a state of "dissociative anaesthesia" characterized electrophysiologically by functional dissociation between the limbic system (which is depressed) and the thalamocortical projection systems (which demonstrate disorganized cataleptic activation). Clinically, the patient appears awake, with spontaneous breathing, intact pharyngeal reflexes, and open eyes with slow horizontal nystagmus, yet is completely dissociated from surrounding sensory and nociceptive stimuli.

• NMDA Receptor Antagonism: Ketamine binds non-competitively to the phencyclidine (PCP) site inside the open channel pore of the ionotropic $N$-methyl-$D$-aspartate (NMDA) receptor complex. This physical channel blockade impedes the influx of $Ca^{2+}$ and $Na^+$ despite agonist binding by glutamate and glycine.
• Secondary Targets: Binds opioid $\mu$ and $\kappa$ receptors (mediating spinal analgesia), interacts with central muscarinic receptors, and blocks neuronal monoamine reuptake transporters, increasing synaptic concentrations of noradrenaline, dopamine, and serotonin.

Organ System Effects and Clinical Pearls

• Cardiovascular Dynamics (The Double-Edged Sword):
  • Indirect Sympathomimetic: In patients with intact sympathetic reserves, ketamine activates central sympathetic outflow from the nucleus tractus solitarius and blocks the neuronal uptake-1 transporter of noradrenaline. This triggers acute increases in systemic blood pressure, heart rate, cardiac output, myocardial oxygen consumption ($MVO_2$), and pulmonary vascular resistance ($PVR$).
  • Direct Myocardial Depressant: In critically ill, catecholamine-depleted patients (e.g., end-stage septic shock, severe multi-trauma, decompensated chronic heart failure), central sympathetic stimulation is exhausted. In this setting, ketamine unmasks its direct negative inotropic effect, precipitating immediate arterial hypotension and cardiovascular collapse.
• Respiratory System: Minimal respiratory depression; tidal volume and respiratory rate are well preserved, and hypercapnic ventilatory drive remains intact. Pharyngeal and laryngeal protective reflexes remain active (although aspiration can still occur). Ketamine is a potent bronchodilator via direct relaxation of bronchial smooth muscle and indirect $\beta_2$-adrenoceptor stimulation via endogenous catecholamine release, making it the induction agent of choice in acute status asthmaticus.
• Neurodynamics: Increases $CMRO_2$, $CBF$, and $ICP$ in spontaneously breathing patients due to cerebral vasodilation secondary to systemic sympathetic stimulation and potential mild hypoventilation. However, in mechanically ventilated patients maintained on normocapnia and co-administered a $GABA_A$ agonist, ketamine-induced $ICP$ elevations are minimal. Increases intraocular pressure ($IOP$).
• Emergence Phenomena: Between 10% and 30% of adult patients experience vivid dreaming, colorful visual or auditory hallucinations, depersonalization, floating sensations, and severe emergence delirium. Emergence delirium is mitigated by pre-treatment with midazolam (1 to 2 mg IV) or propofol.

---

5. Barbiturates: Thiopental and Methohexital

Barbiturates are derivatives of barbituric acid (2,4,6-trioxohexahydropyrimidine). Thiopental is a thiobarbiturate (sulfur atom substituted at position C2), imparting rapid onset and high lipid solubility. Methohexital is an oxybarbiturate (oxygen atom at C2) with a methylated nitrogen at N1, giving it rapid hepatic clearance.

Mechanism of Action and Formulation

• Mechanism: Barbiturates bind allosterically to the $GABA_A$ receptor at sites distinct from benzodiazepines and propofol. They increase the duration of open chloride channel bursts (whereas benzodiazepines increase the frequency of channel opening). At high concentrations, barbiturates directly open $Cl^-$ channels in the complete absence of GABA and depress excitatory AMPA/kainate receptors.
• Formulation: Formulated as sodium salts reconstituted with 6% anhydrous sodium carbonate to maintain an alkaline pH of 10.5 in aqueous solution. This prevents precipitation of the insoluble free acid. Thiopental is chemically incompatible with acidic medications; co-administration with acidic drugs (such as rocuronium, vecuronium, or opioids) in the same IV line produces instantaneous precipitation of a white, insoluble salt precipitate that occludes venous access.

Neuroprotective Actions and Methohexital in ECT

Thiopental induces profound cerebral vasoconstriction, causing parallel reductions in $CBF$, $ICP$, and $CMRO_2$ (up to a 50% ceiling reduction, producing an isoelectric line on electroencephalography). It provides metabolic brain protection during focal cerebral ischemia (e.g., temporary cerebral aneurysm clipping). In contrast, methohexital uniquely lowers the seizure threshold and activates epileptogenic cortical foci; it is the induction agent of choice for electroconvulsive therapy (ECT) to facilitate therapeutic seizure duration.

Intra-Arterial Injection Hazard

Accidental intra-arterial injection (e.g., into an aberrant superficial radial or ulnar artery in the antecubital fossa) represents a catastrophic emergency:

1. Pathophysiology: When the highly alkaline thiopental solution (pH 10.5) enters arterial blood (pH 7.4), the drug immediately shifts into its non-ionized, lipid-soluble free acid form, precipitating into insoluble micro-crystals. These crystals lodge in distal arterioles, triggering intense chemical endarteritis, massive endothelial denudation, severe arterial vasospasm, platelet aggregation, microvascular thrombosis, distal ischemia, and tissue gangrene.
2. Immediate Management Protocol:
   • Leave the arterial cannula in place! Never remove the needle or catheter.
   • Inject vasodilators directly into the artery through the in situ cannula: papaverine (40 mg), lidocaine 1% (50-100 mg), or tolazoline/phenoxybenzamine.
   • Administer heparin intravenously to arrest microvascular thrombosis.
   • Perform a regional sympathetic block (stellate ganglion block for the upper limb or brachial plexus block) to eliminate vasoconstrictive tone.
   • Provide aggressive parenteral analgesia.

Absolute Contraindication in Acute Porphyria

Barbiturates are strictly contraindicated in patients with Acute Intermittent Porphyria (AIP), Variegate Porphyria, or Hereditary Coproporphyria. Barbiturates induce hepatic $\delta$-aminolevulinic acid (ALA) synthetase, the rate-limiting enzyme in heme biosynthesis. In patients with an underlying partial enzymatic deficiency in the heme pathway, induction of ALA synthetase drives massive overproduction and accumulation of neurotoxic porphyrin precursors (porphobilinogen and ALA), precipitating life-threatening neurovisceral attacks characterized by severe abdominal pain, peripheral motor neuropathy, ascending flaccid paralysis, autonomic collapse, and acute delirium.

---

6. Comprehensive Summary Table of Intravenous Induction Agents